SCHEMBL2223368

SCHEMBL2223368

Cc1cc(-c2nc3cnc(Oc4ccccc4)nc3o2)cc(C)c1OCC(=O)O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.83
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.39
HPGDS O60760 2/20 0.38
DHODH Q02127 1/20 0.38
ALDH1A1 P00352 6/20 0.38
CYP1A2 P05177 4/20 0.38
MAPK1 P28482 2/20 0.38
FFAR1 O14842 1/20 0.38
PPARD Q03181 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.36
PTPN1 P18031 1/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 2/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2223316 0.93 S1PR1 (0.75) S1PR1PPARGPPARAKMT2AGAA
SCHEMBL2221025 0.92 S1PR1 (0.83) S1PR1PPARGPPARAKMT2AALDH1A1
SCHEMBL14797145 0.92 S1PR1 (0.77) S1PR1PPARGPPARAKMT2AGAA
SCHEMBL14797011 0.92 S1PR1 (0.82) S1PR1PPARGKMT2AALDH1A1CYP1A2
SCHEMBL2222826 0.91 S1PR1 (0.73) S1PR1PPARGPPARAKMT2ADHODH
SCHEMBL2222062 0.91 S1PR1 (0.82) S1PR1PPARGPPARAKMT2AALDH1A1
SCHEMBL2222592 0.91 S1PR1 (0.81) S1PR1PPARGPPARADHODHFFAR1
SCHEMBL2224170 0.91 S1PR1 (1.00) S1PR1PPARGPPARAKMT2AALDH1A1
SCHEMBL14797136 0.90 S1PR1 (0.71) S1PR1CETPMAPT
SCHEMBL14797017 0.89 S1PR1 (0.73) S1PR1PPARGPPARAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US claimed
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2013-03-28 US claimed
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
US-8846692-B2 Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring SANOFI (FR) 2014-09-30 US disclosed
EP-2523962-B1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI SA (FR) 2013-11-27 EP disclosed
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2013-03-28 US disclosed
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2013-03-28 US disclosed
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2013-03-28 US disclosed
EP-2523962-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI (FR) 2012-11-21 EP disclosed
WO-2011086079-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed
WO-2011086079-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING SANOFI-AVENTIS (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079358-A1 CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING OXGR1, EDNRA, EDF1 S1PR1 129/4885PPARG 334/4885PPARA 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.